Urticaria is a disease characterized by wheals and/or angioedema. Chronic spontaneous urticaria (CSU) occurs for longer than 6 weeks and appears independently of any identifiable exogenous stimulus. During the vaccination campaign for Coronavirus disease 2019 (COVID-19) pandemic, several cutaneous adverse events have been described, among which urticaria lasting less than 6 weeks (acute urticaria, AU). AU due to vaccines can be IgE or non-IgE mediated; the former typically develop within 4 hours of drug exposure, the latter occurs later and the mechanism is unclear. In this retrospective study we analyzed the frequency and clinical characteristics of urticaria occurring after COVID-19 vaccine (post-vaccination urticaria relapse, PVUR) in adult CSU patients treated with antihistamine and omalizumab, and in clinical remission.

Urticaria Relapse after mRNA COVID-19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: a single-center experience / Picone, Vincenzo; Napolitano, Maddalena; Martora, Fabrizio; Guerriero, Luigi; Fabbrocini, Gabriella; Patruno, Cataldo. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2022), p. e15838. [10.1111/dth.15838]

Urticaria Relapse after mRNA COVID-19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: a single-center experience

Picone, Vincenzo;Napolitano, Maddalena;Guerriero, Luigi;Fabbrocini, Gabriella;
2022

Abstract

Urticaria is a disease characterized by wheals and/or angioedema. Chronic spontaneous urticaria (CSU) occurs for longer than 6 weeks and appears independently of any identifiable exogenous stimulus. During the vaccination campaign for Coronavirus disease 2019 (COVID-19) pandemic, several cutaneous adverse events have been described, among which urticaria lasting less than 6 weeks (acute urticaria, AU). AU due to vaccines can be IgE or non-IgE mediated; the former typically develop within 4 hours of drug exposure, the latter occurs later and the mechanism is unclear. In this retrospective study we analyzed the frequency and clinical characteristics of urticaria occurring after COVID-19 vaccine (post-vaccination urticaria relapse, PVUR) in adult CSU patients treated with antihistamine and omalizumab, and in clinical remission.
2022
Urticaria Relapse after mRNA COVID-19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: a single-center experience / Picone, Vincenzo; Napolitano, Maddalena; Martora, Fabrizio; Guerriero, Luigi; Fabbrocini, Gabriella; Patruno, Cataldo. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2022), p. e15838. [10.1111/dth.15838]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/894305
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact